Syndetics cover image
Image from Syndetics

F. Hoffman-LaRoche Ltd. : Avastin and a crisis in patient blindness / Sourya Biswas, Mike Gedjeyan, James S. O'Rourke.

By: Contributor(s): Material type: TextSeries: Publisher: London : SAGE Publications Ltd, 2017Description: 1 online resource : illustrationsContent type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781526408464 (ebook) :
Subject(s): DDC classification:
  • 338.476151091724
Online resources: In spite of similar formulation, Swiss pharmaceutical's giant Roche has always positioned its two products Avastin and Lucentis separately, as treatments for cancer and for age-related macular degeneration (AMD) respectively. However, doctors have been prescribing Avastin for AMD treatments because of the huge price differential between the two drugs. With contamination of Avastin due to repackaging by a Florida pharmacy leading to 21 cases of patient blindness in Q3 2011, Roche faces a serious threat to its reputation and finances.
No physical items for this record

Originally published in Biswas, S., Gedjeyan, M., & ORourke, J. S. (2011). F. Hoffman-LaRoche Ltd.: Avastin and a crisis in patient blindness. 11-09. Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.

In spite of similar formulation, Swiss pharmaceutical's giant Roche has always positioned its two products Avastin and Lucentis separately, as treatments for cancer and for age-related macular degeneration (AMD) respectively. However, doctors have been prescribing Avastin for AMD treatments because of the huge price differential between the two drugs. With contamination of Avastin due to repackaging by a Florida pharmacy leading to 21 cases of patient blindness in Q3 2011, Roche faces a serious threat to its reputation and finances.

Description based on XML content.

Licensed e-book